Market Analysis Open Access

Market Analysis of the 8th Global Conference on Mass Spectrometry


Dr. Tatsuya Fujino

Associate Professor, TokyoMetropolitan University, Meguro City, Tokyo 152-8550, Japan, E-mail: fujino048@toyo.jp

Mass Spectrometry Market

The mass spectrometry market is expected to witness the CAGR of 7.27% during the forecast period. Certain factors that are driving the market growth include the increasing technological advancement, growing concerns over food safety, and rising R&D expenditure by the pharmaceutical industry and government research organizations.

Mass spectrometry (MS) is one of the most powerful tools used for the analyses of a wide range of chemical and biological entities. In addition, the high demand and resulting requirements from the pharmaceutical and biotechnology industries are the main driving factors for some extraordinary recent advances in mass spectrometry technology. The advancements in mass spectroscopy technology were able to increase the factors like rapid test results with high resolution. The discovery of new tools and software has the potential to stimulate the usage of mass spectroscopy across drugs development, proteomics, pharmaceuticals, food safety testing, and many other fields. The demands of the life sciences applications have led to the improvement of MS technologies and the rapid growth of new types of instruments. New mass spectrometry methods, collectively known as data independent analysis and hyper reaction monitoring, have recently emerged. Understanding complexity related to cancer biology requires extensive information about the cancer proteome over the course of the disease. Hence, with the increasing technological advancement, the market is expected to grow.



Scope of the Report

As per the scope of this report, mass spectrometry (MS) is an analytical chemistry technique used to identify the amount and type of chemical species present in a sample, by measuring the mass to charge ratio and abundance of gas phase ions.

Key Market Trends

Triple Quadrupole (Tandem) is Expected to Hold Significant Market Share from the Types of Hybrid Mass Spectrometry.

Tandem mass spectrometry devices are currently among the most in demand. Conventional hospital diagnostic assays are based on clinical chemistry and immunoassay techniques that require analyte specific reagents and antibodies. LC-MS/MS-based approaches are considered reagent free. The high specificity and sensitivity of LC-MS/MS overcome many limitations associated with the traditional immunoassays, such as non specific antibody binding and cross reactivity. There is a higher demand for hybrid instruments, such as triple quadrupole mass spectrometer, quadrupole time of flight mass spectrometer, etc. Currently, triple quadrupole MS is considered one of the most high end instruments and many labs across the world are adopting this instrument.

Market Growth of Mass spectrometry Research in the previous and upcoming ten years:

The global mass spectrometry market was valued at \$4,948.3 million in 2015, and it is anticipated to develop at a CAGR of 8.1% throughout the duration 2016-2022.

The global market is increasing, due to growing food safety concern, developing demand in life science & scientific analysis sector, & growing healthcare expenditure & improvement of healthcare infrastructure.

In addition, the technological developments with the advent of Mass Spectrometry equipment are in addition encouraging the boom of the market.

This report studies the global mass spectrometry market for the forecast duration of 2015 to 2020. This market is expected to reach USD 7,279.1 Million by 2020 from USD 4,919.9 in 2015 at a CAGR of 8.1% during the forecast period.

Market Value on Pharmaceutical Research:

According to the World Health Organization, The global pharmaceuticals market is worth \$300 billion a year, a figure that is expected to rise to \$400 billion within three years. The 10 largest drugs companies in this sector have control over one third of this market, several with the sales of more than \$10 billion a year and profit margins of about 30%. Six are based totally in the United States and four in Europe. It is anticipated that North and South America, Europe, and Japan will proceed

to account for a full 85% of the world pharmaceuticals market properly into the 21st century.

North America Dominates the Market & Expected to do same in the Forecast Period

According to the Industrial Research Institute (IRI) report, the United States spends the world's highest (i.e., USD 516 billion) amount for research and development, currently. The United States spends 43% of the total life sciences/healthcare research and development and 56% of pharmaceutical/biotech R&D spending worldwide. Research and development include drug development and fundamental science research. Drug development, from the initial discovery to the final medication, is an expensive and lengthy process, and the failure rate is also high. High cost, lengthy time period, and the high failure rate are forcing researchers and drug manufacturing companies to look for newer technology, which can improve the process and reduce the cost at the same time. Mass spectrometry has the potential to do the same. It makes a functional and structural study, which takes a significant amount of time and resource in drug development, for the molecule, easier and faster.



Competitive Landscape

The mass spectrometry market is very competitive and consists a small number of major players. Companies like Agilent Technologies, Bruker Corporation, Danaher Corporation, Dani instruments s.p.a, Leco Corporation, Perkin Elmer Inc., Shimadzu Corporation, Thermo Fisher Scientific, and Waters Corporation, among others, hold the substantial market share in the mass spectrometry market.